Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
3 August 2020
The Pathologist reports on research, innovations, personalities, and policies that shape pathology. Each year The Pathologist celebrates 100 inspirational and influential professionals in laboratory medicine.
Professor Scolyer has been recognised in the Big Breakthroughs category, due to his cutting-edge research discoveries that have changed clinical and pathology practice worldwide. He is a leader in determining mechanisms of enhanced response versus resistance to drugs in development, such as immunotherapies – data that underpins the design of current clinical trials.
A world leader in melanoma pathology, Professor Scolyer provides a clinical consultation service for the diagnosis of difficult pigmented lesions, receiving over 2,000 cases from around the world each year.
“My biggest influence has been the Melanoma Institute Australia Research Database that was set up by the late Gerry Milton 60 years ago,” Professor Scolyer says. “This is now the largest melanoma patient database in the world, with over 50,000 patients, and is a major international resource that has provided me with many opportunities to perform important research that correlates pathological and clinical features with patient outcome data in large cohorts.
“Whatever you do, make sure you enjoy the process – because it’s through passion and fulfilment that you will have success and achieve things,”
And Professor Scolyer’s biggest wish? “That people of all ages, but especially young people, were more vigilant in protecting themselves from the sun. UV exposure leading to sunburn is the single biggest risk factor for developing melanoma, which claims one Australian life every five hours.”
See the full 2020 Power List here: https://thepathologist.com/power-list/2020
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina this October, to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Melanoma research saved Bert's life at 101 and now he wants to give back.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.